Tethis operates in the diagnostic sector, developing a preanalytical system for liquid biopsy and methodology of capture and analysis of circulating tumours cells, based on proprietary technology.

The company began to develop methodologies for the analysis of liquid biopsies in 2018, during 2019 and 2020, tests on pathologies obtained important results, in particular the experimentation regarding breast cancer.

Overall, the global liquid biopsy market is worth around 4 billion and is expected to exceed 15 billion in 2022.

Atlante Ventures participated in a round in 2010 to support the development of microFind™, an innovative device for improving the Fluorescent in Situ Hybridization (FISH) technology. In September 2020 Indaco Ventures I entered to support the development of clinical trials and prepare the company for the clinical phase.